Orexo AB (publ) (0H19.L)

20.50 -0.85 (-3.98%) At close: 04:50PM GMT

Orexo AB (publ)

P.O. Box 303
Uppsala 751 05
Sweden
46 1 87 80 88 00
https://www.orexo.com

Sector(s): 
Industry: 
Full-time employees: 126

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Nikolaj Sorensen	Pres & CEO	5.83M	N/A	1972
Mr. Fredrik Jarrsten	Exec. VP & CFO	N/A	N/A	1967
Ms. Cecilia Coupland	Sr. VP & Head of Operations	N/A	N/A	1976
Lena Wange	Investor Relations & Communications Director	N/A	N/A	N/A
Mr. Robert Ronn	Sr. VP and Head of R&D	N/A	N/A	1976
Mr. Dennis Urbaniak	Exec. VP of Digital Therapeutics	N/A	N/A	1969
Dr. Edward Kim M.B.A., M.D.	Chief Medical Officer	N/A	N/A	N/A
Mr. Robert A. Deluca	Pres of Orexo US Inc	N/A	N/A	1961
Mr. Jesper Lind	Advisor	N/A	N/A	1960

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Corporate governance

Orexo AB (publ)’s ISS governance QualityScore as of 28 January 2023 is 2. The pillar scores are Audit: 8; Board: 1; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.